Colonic Motility in Patients With Diabetes



Gastrointestinal (GI) symptoms are overrepresented in patients with diabetes mellitus (DM) and often have a major impact on quality of life. Typical symptoms of diabetic enteropathy include abdominal pain, nausea, vomiting, diarrhoea, constipation, faecal incontinence, and bloating. Bowel symptoms in DM are usually caused by widespread dysfunction of the GI tract, but the exact pathophysiology remains incompletely understood. Within recent years, new methods for detailed assessment of GI motility have been developed. Hence, the electromagnetic 3D-Transit system is a safe, non-invasive method for detailed description of GI motility. The system tracks the exact position of an ingested electromagnetic capsule through the entire GI tract and provides detailed information on both regional transit- and contraction patterns. High Resolution Colonic Manometry (HRCM) allows extremely detailed description of contraction patterns in the colon. The HRCM is however an invasive method, as the catheter is placed during colonoscopy. HRCM has not previously been performed on diabetic patients and 3D-Transit has only been used sparingly.

Study Objectives:

The purpose of this study is to obtain detailed description of colonic contractions in patients with DM and gastrointestinal symptoms, especially during fast and after meals.


1. Patients with DM and GI symptoms have reduced high-amplitude, antegrade contractions in the colon when compared to healthy controls (HRCM).

2. Patients with DM and GI symptoms have reduced long, fast mass-movements when compared to healthy controls (3D-Transit).

3. The contractile response to a meal is reduced in patients with symptoms of diabetic enteropathy when compared to healthy controls.

Materials and methods:

20 patients with DM type 1 or 2 and GI symptoms will be investigated simultaneously HCRM and the 3D-Transit capsule. Data will be compared to the healthy from another study (CIV-19-05-028726). A colonoscopy is performed to install the HRCM catheter and place two 3D-Transit capsules within the colon. For 24 hours, the participants lie in a bed in the research lab while pressure changes from the HRCM catheter are recorded and the 3D-Transit capsules are followed through the gastrointestinal system.


The study will add to the very limited data available on colonic dysfunction in DM.

Full Title of Study: “Assessment of Colonic Motility in Patients With Diabetes Using High Resolution Colonic Manometry and 3D-Transit.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 15, 2022


  • Device: High Resolution Colonic Manometry and 3D-Transit system.
    • Not performed as an intervention, the study is observational.

Clinical Trial Outcome Measures

Primary Measures

  • High amplitude, antegrade contractions assessed with HRCM
    • Time Frame: All 24 hours of HRCM and 3D-Transit recording
    • Quantity, amplitude and duration of the high amplitude, antegrade propagating contractions accessed with HRCM, when compared to healthy controls.

Secondary Measures

  • Long, fast mass-movements assessed with 3D-Transit
    • Time Frame: All 24 hours of HRCM and 3D-Transit recording.
    • Quantity and length of the long, fast mass-movements assessed with 3D-Transit, when compared to healthy controls.
  • Distance of capsule movement.
    • Time Frame: All 24 hours of HRCM and 3D-Transit recording.
    • How do the length of a pressure change measured by HRCM correlate with the distance covered in long fast antegrade movements determined with the 3D-Transit system (cm).

Participating in This Clinical Trial

Inclusion Criteria

  • Type 1 or 2 diabetes (at least 3 years since diagnosis)
  • Age between 18 and 70
  • Gastrointestinal symptoms with a weighted and combined symptomscore >2,3 (assessed with The Gastrointestinal Symptom Rating Scale and The Gastroparesis Cardinal Symptom Score).
  • Psychologically able to give an informed content.

Exclusion Criteria

  • Known gastrointestinal disease
  • Intake of medication with known effects on the motility patterns in the gastrointestinal system.
  • Dysregulated hyperthyroidism or hypothyroidism.
  • Any disease known to cause gastroparesis (Parkinson's disease, scleroderma, etc.)
  • Pacemaker/ICD
  • A scheduled MRI scan within 4 weeks after trial initiation.
  • Abdominal circumference >140cm
  • Pregnancy and lactation
  • Unable to follow the scheduled program in the trial due to mental illness or instability.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Investigator Details

  • Lead Sponsor
    • University of Aarhus
  • Collaborator
    • Aalborg University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Klaus Krogh, MD, ph.d., Study Chair, Overall scientific leadership of the protocol
  • Overall Contact(s)
    • Ditte S Iversen, MD, 40517858,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.